Australian hi-tech company Micro-X Ltd (ASX:MX1) it has signed its first contract for sales of its second product, the Rover.
Micro-X*,* a leader in cold cathode x-ray technology for health and security markets globally, has received a $1.4 million contract facilitated by World Health Organisation for Rover X-ray units*.*
Managing Director, Peter Rowland, said that since the company received FDA clearance in July 2020, Micro-X has been focussing most of its sales efforts on securing Rover business with its target military customers in the Australian, US and UK armed forces.
In addition, the Micro-X sales team has been exploring other deployable applications where the rugged and independent operational capabilities of the Rover offer practical customer benefits.
Mr Rowland said this agreement for sales of Rover with WHO demonstrates the attractiveness of Rover’s flexibility and extreme mobility across a broad range of operational scenarios. Deliveries, via an in-country agent, are destined for the Governments of a number of Pacific Island nations and are due to be made from Adelaide in the next four weeks.This marks a first success for the company’s new direct marketing strategy for Rover which enables the company to move up the value-chain compared to its earlier OEM business model.
The need for a full-performance, digital, mobile medical x-ray imager, ruggedised and light enough to be used in deployed or temporary medical facilities was first identified to the company by the Australian Army.
The ‘Rover’ product was subsequently developed under a contract from the Australian Department of Defence which proved that Micro-X’s technology could fulfil this operational requirement.
The Rover’s design incorporates the core elements of Micro-X’s first bedside imaging product and has attracted acclaim for the focus on rugged construction, operator workflow features, manoeuvrability, long-life battery operation and other specialised features for robust mobility on uneven and temporary surfaces.
Achieving this first deal for the Rover product less than 2 months after receiving FDA clearance is a significant step for Micro-X as we further grow revenue and become a commercially focused technology business,” Mr Rowland said.
“This contract also marks an important milestone in the growth of our internal sales capability as we embark on an aggressive sales strategy for the Rover product. We are delighted with the positive feedback received for Rover and we aim to sustain this revenue momentum throughout the financial year.”
https://micro-x.com/
